Here are the latest G-BA decisions from the G-BA meeting held on 17 April 2025 on the early benefit assessments of Vaborem, Vyloy, Artesunate Amivas, and Tepkinly.
A complete database of all previous G-BA resolutions is in my membership.
- Vaborem (meropenem/vaborbactam); bacterial infections, multiple indications – Reserve antibiotic, Additional benefit deemed proven across all 5 subgroups
- Vyloy (zolbetuximab); adenocarcinoma of the stomach or gastroesophageal junction – Orphan drug, Indication of minor additional benefit
- Artesunate Amivas (artesunate); severe malaria, from birth – Orphan drug, Not-quantifiable additional benefit, no dossier submitted
- Tepkinly (epcoritamab); diffuse large B-cell lymphoma (DLBCL), after ≥ 2 prior therapies – Re-assessment after revocation of regulatory orphan status, Additional benefit not proven in both subgroups
- Talvey (talquetamab); multiple myeloma, at least 3 prior therapies – Request for RWE data collection withdrawn, prescribing restrictions lifted
Follow me on Instagram to never miss the latest G-BA decisions: